Medibio Ltd (ASX:MEB) provided an update on its breakthrough device designation with the US FDA. The company received notification from the FDA stating that MEB-001, in its current form, does not meet the criteria for designation as a breakthrough device. Medibio expects to schedule a pre-submission meeting with the regulatory body during Q4 CY2023.
Supported by
<SPON> Trade share CFDs with Plus500
Global online trading services company, Plus500:
Plus500 trading platform allows you to trade shares from all popular markets such as USA, UK, Germany and more, with leverage and low spreads. Using our advanced trading tools, you can also control your profits and losses.
Plus500AU Pty Ltd, AFSL #417727 issued by Australian Securities and Investments Commission. Based in Sydney.
Subscribe to the newsletter
Receive whispers every day in your inbox.